Blossom Genetics Announces Appointment to its Board of Advisors
Blossom Genetics announces the appointment of Robert Burton to their Board of Advisors. Robert joins with over 20 years’ experience in international scientific engagement and regulation across the pharmaceutical industry.
PRESS RELEASE 11 AUGUST 2020 – LONDON, UK
Robert was the Group Director of Science & Innovations at Nerudia from 2016-2019. During this time Rob led the global science and regulatory development for innovations across Vape, Oral Nicotine, Heated Tobacco and CBD, which included a period of time based in Washington D.C. where he was responsible for developing the company’s FDA multi-platform engagement strategy. Nerudia was acquired by Imperial Tobacco in 2017.
Prior to this role, Rob was based in America with US-based electronic cigarette company White Cloud, where, for three years, he headed up Corporate and Regulatory Affairs. Rob joined White Cloud, after five years with British American Tobacco, where he was Group Head of Public Health and Scientific Affairs leading a team of industry respected scientists focused upon delivering BAT’s Global external scientific engagement.
Before joining BAT in 2008, he spent over 20 years working in the pharmaceutical sector for AstraZeneca and SmithKline Beecham (GSK). During this time, Rob held several international commercial and scientific roles, including Global Commercial Director for Respiratory Products with AstraZeneca as well as General Manager and Area Director for Eastern European markets with both SmithKline Beecham and AstraZeneca.
Robert has also held non-executive roles with several biotech start-up companies and regularly consults in both Commercial and Regulatory disciplines in the UK and Europe.
Robert is currently on the Board of Directors of AAN Medical Ltd and is a member of the Advisory Board & Scientific Panel of Cannabis for Children (NFP) and a member of the medical Cannabis Clinicians’ Society.
“We are excited to welcome Rob to our board of advisors during an important time in Blossom’s continued evolution,” said Oskar Fletcher CEO of Blossom. “Rob is a recognised leader in the pharmaceutical industry whose extensive commercial and corporate strategy experience will be instrumental in 2020 and beyond as we execute on our vision of delivering superior medical cannabis genetics and products.”
Robert Burton added “I am very excited to have the opportunity to be involved in the growth of this truly innovative company; fully utilising years of experience in plant genetics to develop sector leading initiatives in the medical cannabis industry”
For further information:
Oskar Fletcher, CEO, Blossom Genetics Corporation Limited
# # #
About Blossom Genetics
Blossom delivers the industry’s best cannabis genetics, plants & technical support to companies around the globe. Our mission is to advance medicinal cannabis through scientific research to develop best in class products for our customers.
Our founders are one of the largest soft fruit growers and breeders in Europe. As industry leaders with over 50 years experience we bring our experience and knowledge to produce the highest quality medical products in an industry that has historically lacked best in class standards.
We started Blossom Genetics as our technology and knowhow will produce a superior product and ultimately benefit patients and improve their wellbeing.
Through research, education, and knowledge-sharing, we’re inspiring new thinking and informed decisions about medical cannabis and health. Learn more at www.blossomgenetics.com and follow us on Twitter @BlossomGenetics.